| 6.75 -0.44 (-6.12%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.15 | 1-year : | 8.35 |
| Resists | First : | 6.12 | Second : | 7.15 |
| Pivot price | 5.43  |
|||
| Supports | First : | 4.94 | Second : | 4.21 |
| MAs | MA(5) : | 5.62  |
MA(20) : | 5.25 |
| MA(100) : | 5.07 |
MA(250) : | 4.07 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 72.8 |
D(3) : | 77.4 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 8.35 | Low : | 2.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATHA ] has closed above bottom band by 45.6%. Bollinger Bands are 6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.57 - 5.6 | 5.6 - 5.63 |
| Low: | 5.03 - 5.07 | 5.07 - 5.1 |
| Close: | 5.29 - 5.35 | 5.35 - 5.4 |
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.
Fri, 09 Jan 2026
Athira Pharma (ATHA) Stock Price, News & Analysis - Stock Titan
Fri, 09 Jan 2026
Biotech behind new breast cancer trial takes on a new name - Stock Titan
Fri, 09 Jan 2026
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
Thu, 18 Dec 2025
Athira Pharma raises $90 million as Bothell firm shifts focus - bizjournals.com
Thu, 18 Dec 2025
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 85.5 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 71 (K) |
| EPS | -9.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|